Business
-
GlaxoSmithKline and Theravance have announced the availability of the Breo Ellipta fluticasone furoate/vilanterol DPI in the US. The FDA approved Breo Ellipta for the treatment of COPD in May 2013. The launch triggers a $30… Read more . . .
-
Depomed has announced a new launch of Lazanda fentanyl nasal spray in the US for the management of breakthrough pain in cancer patients who get inadequate relief from opioids. The company acquired the product from… Read more . . .
-
Alexza Pharmaceuticals and Grupo Ferrer have launched Adasuve loxapine inhalation powder for the treatment of agitation in schizophrenic patients in Austria, the companies said. Ferrer is working with Vienna-based AOP Orphan Pharmaceuticals to commercialize Adasuve… Read more . . .
-
Acacia Research has announced a settlement in its patent infringement suit against AstraZeneca. The suit, Accuhale vs. AstraZeneca, was filed in December 2011, shortly after Acacia announced that it had acquired patents for inhaler technology… Read more . . .
-
Cystic Fibrosis Foundation Therapeutics (CFFT) has awarded Savara Pharmaceuticals $1.7 million for further development of AeroVanc inhaled vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis patients. CFFT is a… Read more . . .
-
Insmed has announced that it anticipates discussions with the EMA by the end of 2013 regarding Arikace inhaled liposomal amikacin for the treatment of nontuberculous mycobacterial (NTM) lung disease and that it has already initiated… Read more . . .
-
Under a new joint venture, Harmony Asset will pay development costs for Dance Biopharm’s Adagio inhaled insulin in Asian countries, including Korea, India, Indonesia and Australia, Dance has announced. The agreement excludes Japan. Harmony will… Read more . . .
-
Nephron Pharmaceuticals has announced a voluntary recall of ten lots of albuterol inhalation solution “as a precautionary measure, due to results from . . . internal monitoring processes.” The company says that it has not… Read more . . .
-
Sanofi has announced today that its Nasacort Allergy 24HR triamcinolone acetonide nasal spray for the treatment of nasal allergies will be available over-the-counter beginning in spring 2014 now that the FDA has approved it as… Read more . . .
-
During a recent web presentation on its respiratory R&D activities, Teva announced that it plans to make 13 regulatory submissions for respiratory products over the next 5 years, introduce “proprietary devices addressing unmet needs,” and… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.